Matches in Wikidata for { <http://www.wikidata.org/entity/Q66038553> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q66038553 description "assaig clínic" @default.
- Q66038553 description "clinical trial" @default.
- Q66038553 description "clinical trial" @default.
- Q66038553 description "clinical trial" @default.
- Q66038553 description "clinical trial" @default.
- Q66038553 description "ensaio clínico" @default.
- Q66038553 description "ensayo clínico" @default.
- Q66038553 description "ensayu clínicu" @default.
- Q66038553 description "essai clinique" @default.
- Q66038553 description "klinisch onderzoek" @default.
- Q66038553 description "клінічне випробування" @default.
- Q66038553 description "կլինիկական փորձարկում" @default.
- Q66038553 name "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia" @default.
- Q66038553 name "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia" @default.
- Q66038553 type Item @default.
- Q66038553 label "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia" @default.
- Q66038553 label "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia" @default.
- Q66038553 prefLabel "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia" @default.
- Q66038553 prefLabel "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia" @default.
- Q66038553 P1050 Q66038553-E78E9662-7713-46B6-98BF-CB220DE65539 @default.
- Q66038553 P1132 Q66038553-1731D371-E416-456C-87EC-A86F8AEC540C @default.
- Q66038553 P1476 Q66038553-FDD85F16-8979-4221-BDCB-20C4D2635223 @default.
- Q66038553 P2899 Q66038553-0194A750-0E41-43F5-90A5-86DD03916620 @default.
- Q66038553 P3098 Q66038553-FA86985E-A976-4409-89F2-688F6094714A @default.
- Q66038553 P31 Q66038553-5B5F4B1C-ACA8-475F-97B3-D19514F4EBE6 @default.
- Q66038553 P4135 Q66038553-EAB1C0FA-967E-4A63-A321-8DE2935AC705 @default.
- Q66038553 P4844 Q66038553-7D6F97BC-48DE-4F77-8CB6-E89F00B36FB3 @default.
- Q66038553 P582 Q66038553-298DFDAD-CCE4-48EA-A8F3-8CEFE44B0012 @default.
- Q66038553 P6099 Q66038553-78CE266E-32DD-47C3-A765-50F529BE47C8 @default.
- Q66038553 P8363 Q66038553-947F47FD-A987-497B-A6E6-35D36E760CAE @default.
- Q66038553 P1050 Q29496 @default.
- Q66038553 P1132 "+69" @default.
- Q66038553 P1476 "A Dose-Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (go) Given in Combination With Cytarabine and Daunorubicin in Relapsed or Refractory Patients and in Younger de Novo Patients With Acute Myeloid Leukemia (AML)" @default.
- Q66038553 P2899 "+18" @default.
- Q66038553 P3098 "NCT00037583" @default.
- Q66038553 P31 Q30612 @default.
- Q66038553 P4135 "+59" @default.
- Q66038553 P4844 Q412685 @default.
- Q66038553 P582 "2003-09-01T00:00:00Z" @default.
- Q66038553 P6099 Q42824440 @default.
- Q66038553 P8363 Q78089383 @default.